211 related articles for article (PubMed ID: 28285913)
1. Recent progress in prodrug design strategies based on generally applicable modifications.
Hamada Y
Bioorg Med Chem Lett; 2017 Apr; 27(8):1627-1632. PubMed ID: 28285913
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches for designing 5'-O-ester prodrugs of 3'-azido-2', 3'-dideoxythymidine (AZT).
Parang K; Wiebe LI; Knaus EE
Curr Med Chem; 2000 Oct; 7(10):995-1039. PubMed ID: 10911016
[TBL] [Abstract][Full Text] [Related]
3. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
4. New 3'-azido-3'-deoxythymidin-5'-yl O-(omega-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation.
Vlieghe P; Bihel F; Clerc T; Pannecouque C; Witvrouw M; De Clercq E; Salles JP; Chermann JC; Kraus JL
J Med Chem; 2001 Mar; 44(5):777-86. PubMed ID: 11262088
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine.
Saboulard D; Naesens L; Cahard D; Salgado A; Pathirana R; Velazquez S; McGuigan C; De Clercq E; Balzarini J
Mol Pharmacol; 1999 Oct; 56(4):693-704. PubMed ID: 10496951
[TBL] [Abstract][Full Text] [Related]
6. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF
Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410
[TBL] [Abstract][Full Text] [Related]
7. Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate.
Song H; Johns R; Griesgraber GW; Wagner CR; Zimmerman CL
Pharm Res; 2003 Mar; 20(3):448-51. PubMed ID: 12669967
[TBL] [Abstract][Full Text] [Related]
8. Self-assemblies of 5'-cholesteryl-ethyl-phosphoryl zidovudine.
Du L; Jia J; Ge P; Jin Y
Colloids Surf B Biointerfaces; 2016 Dec; 148():385-391. PubMed ID: 27636322
[TBL] [Abstract][Full Text] [Related]
9. Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug.
Jin Y; Xin R; Tong L; Du L; Li M
Mol Pharm; 2011 Jun; 8(3):867-76. PubMed ID: 21553876
[TBL] [Abstract][Full Text] [Related]
10. Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs.
McIntee EJ; Remmel RP; Schinazi RF; Abraham TW; Wagner CR
J Med Chem; 1997 Oct; 40(21):3323-31. PubMed ID: 9341906
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).
Li W; Chang Y; Zhan P; Zhang N; Liu X; Pannecouque C; De Clercq E
ChemMedChem; 2010 Nov; 5(11):1893-8. PubMed ID: 20936623
[TBL] [Abstract][Full Text] [Related]
12. Self-assembled drug delivery systems. Part 4. In vitro/in vivo studies of the self-assemblies of cholesteryl-phosphonyl zidovudine.
Jin Y; Xing L; Tian Y; Li M; Gao C; Du L; Dong J; Chen H
Int J Pharm; 2009 Oct; 381(1):40-8. PubMed ID: 19646518
[TBL] [Abstract][Full Text] [Related]
13. A step further in the SATE mononucleotide prodrug approach.
Peyrottes S; Villard AL; Coussot G; Augustijns P; Lefebvre I; Aubertin AM; Gosselin G; Périgaud C
Nucleic Acids Symp Ser (Oxf); 2008; (52):539-40. PubMed ID: 18776492
[TBL] [Abstract][Full Text] [Related]
14. Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine.
Skoblov Y; Karpenko I; Shirokova E; Popov K; Andronova V; Galegov G; Kukhanova M
Antiviral Res; 2004 Aug; 63(2):107-13. PubMed ID: 15302139
[TBL] [Abstract][Full Text] [Related]
15. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.
Santos C; Morais J; Gouveia L; de Clercq E; Pannecouque C; Nielsen CU; Steffansen B; Moreira R; Gomes P
ChemMedChem; 2008 Jun; 3(6):970-8. PubMed ID: 18389514
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine.
Kong L; Cooperwood JS; Huang SH; Chu CK; Boudinot FD
Antivir Chem Chemother; 2003 Sep; 14(5):263-70. PubMed ID: 14694989
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro chemical and enzymatic stability of glycosyl 3'-azido-3'-deoxythymidine derivatives as potential anti-HIV agents.
Bonina F; Puglia C; Rimoli MG; Avallone L; Abignente E; Boatto G; Nieddu M; Meli R; Amorena M; de Caprariis P
Eur J Pharm Sci; 2002 Aug; 16(3):167-74. PubMed ID: 12128171
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and preliminary evaluation of anti-HIV agent AZT prodrug.
Cui QB; Zhang GX; Yu P; Wang YQ
Yao Xue Xue Bao; 2011 Aug; 46(8):1015-8. PubMed ID: 22007530
[TBL] [Abstract][Full Text] [Related]
19. Novel prodrugs with a spontaneous cleavable guanidine moiety.
Hamada Y
Bioorg Med Chem Lett; 2016 Apr; 26(7):1685-9. PubMed ID: 26923694
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside diphosphate prodrugs.
Meier C; Jessen HJ; Balzarini J
Nucleic Acids Symp Ser (Oxf); 2008; (52):83-4. PubMed ID: 18776264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
